Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to beat staph blood infections

NCT ID NCT06958835

Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests whether adding the antibiotic linezolid to standard treatment improves outcomes for people with Staphylococcus aureus bloodstream infections. About 606 hospitalized adults will receive either linezolid or a placebo for five days. The goal is to see if the combination reduces complications, helps patients return to normal function, and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
linezolid
What this could lead to
If it works, this could lead to a better treatment strategy for serious staph bloodstream infections, reducing complications and improving survival.
What could go wrong
This is a mid-stage trial, so results may not confirm benefit. Adding linezolid also carries risks like side effects or drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 606 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Staphylococcus aureus (S. aureus) grown from at least one blood culture * Hospitalised at a participating centre * ≥18 years old * Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements Exclusion criteria: * Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus * Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment * Necrotising fasciitis * Currently receiving linezolid or clindamycin * Use of any monoamine oxidase A or B inhibitor within the last two weeks * Known hypersensitivity to linezolid or any other ingredients of the study drugs * Current severe thrombocytopenia (i.e. \<30 x 10\^9/L) * Application of study drug not possible (per mouth or per gastric tube) * Currently breastfeeding * Local treating team believes that death is imminent and inevitable * Patient is receiving end of life care and antibiotic treatment is not considered appropriate * Local treating team believes that participation in the study is not in the best interest of the patient * Any indication that the patient is unwilling to participate in the study including an advance directive stating such unwillingness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Staphylococcus aureus bloodstream infections (bsi; bacteremia) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis Sepsis staphylococcal infection staphylococcus aureus infection Toxemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Staphylococcus aureus bloodstream infections (bsi; bacteremia)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre hospitalier universitaire vaudois (CHUV)

    RECRUITING

    Lausanne, Canton of Vaud, Switzerland

  • Ente Ospedaliero Cantonale (EOC)

    RECRUITING

    Lugano, Canton Ticino, Switzerland

  • HOCH Health Ostschweiz, Kantonsspital St.Gallen

    RECRUITING

    Sankt Gallen, Canton of St. Gallen, Switzerland

  • Hôpital du Jura

    RECRUITING

    Delémont, Canton of Jura, Switzerland

  • Hôpitaux universitaires de Genève (HUG)

    RECRUITING

    Geneva, Canton of Geneva, Switzerland

  • Inselspital Bern

    RECRUITING

    Bern, Canton of Bern, Switzerland

  • Kantonsspital Aarau (KSA)

    RECRUITING

    Aarau, Canton of Aargau, Switzerland

  • Kantonsspital Winterthur (KSW)

    RECRUITING

    Winterthur, Canton of Zurich, Switzerland

  • St. Claraspital

    RECRUITING

    Basel, Canton of Basel-City, Switzerland

  • Stadtspital Zürich Triemli

    RECRUITING

    Zurich, Canton of Zurich, Switzerland

  • University Hospital Basel (USB)

    RECRUITING

    Basel, 4031, Switzerland

  • Universitätsspital Zürich (USZ)

    RECRUITING

    Zurich, Canton of Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.